Comparative functional analysis of CYP71AV1 natural variants reveals an important residue for the successive oxidation of amorpha-4,11-diene  by Komori, Aya et al.
FEBS Letters 587 (2013) 278–284journal homepage: www.FEBSLetters .orgComparative functional analysis of CYP71AV1 natural variants reveals an
important residue for the successive oxidation of amorpha-4,11-diene0014-5793/$36.00  2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2012.11.031
Abbreviations: abCYP71AV1, CYP71AV1 isolated from A. absinthium; Aldh1,
aldehyde dehydrogenase; ADS, amorpha-4,11-diene synthase; afCYP71AV1,
CYP71AV1 isolated from A. afra; CPR, cytochrome P450 reductase; Dbr2, artemisinic
aldehyde D11(13) reductase; FDP, farnesyl diphosphate; SRSs, substrate-recogni-
tion sites
⇑ Corresponding author. Fax: +81 6 6879 7426.
E-mail address: muranaka@bio.eng.osaka-u.ac.jp (T. Muranaka).Aya Komori a,b,d, Munenori Suzuki a,d, Hikaru Seki a,c,d, Tomoko Nishizawa c,
Jacobus Johannes Marion Meyer e, Hideaki Shimizu b, Shigeyuki Yokoyama b, Toshiya Muranaka a,c,d,⇑
aKihara Institute for Biological Research, Yokohama City University, Maioka-cho 641-12, Totsuka-ku, Yokahama, Kanagawa 244-0813, Japan
bRIKEN Systems and Structural Biology Center, Suehiro-cho 1-7-22, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
cRIKEN Plant Science Center, Suehiro-cho 1-7-22, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
dDepartment of Biotechnology, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
eDepartment of Plant Science, University of Pretoria, Lynnwood Road, Pretoria 0002, South Africaa r t i c l e i n f o
Article history:
Received 3 October 2012
Revised 29 November 2012
Accepted 29 November 2012
Available online 13 December 2012







Successive oxidationa b s t r a c t
Artemisinin is an antimalarial sesquiterpenoid isolated from the aerial parts of the plant Artemisia
annua. CYP71AV1, a cytochrome P450 monooxygenase was identiﬁed in the artemisinin biosyn-
thetic pathway. CYP71AV1 catalyzes three successive oxidation steps at the C12 position of
amorpha-4,11-diene to produce artemisinic acid. In this study, we isolated putative CYP71AV1
orthologs in different species of Artemisia. Comparative functional analysis of CYP71AV1 and its
putative orthologs, together with homology modeling, enabled us to identify an amino acid residue
(Ser479) critical for the second oxidation reaction catalyzed by CYP71AV1. Our results clearly show
that a comparative study of natural variants is useful to investigate the structure–function relation-
ships of CYP71AV1.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Artemisinin, a sesquiterpene endoperoxide lactone, was identi-
ﬁed from Artemisia annua L. (Asteraceae) as a compound that is
highly effective against Plasmodium spp., the parasite that causes
malaria [1]. Because artemisinin and its analogs derivatives are
highly poisonous, they are effective against multidrug-resistant
Plasmodium falciparum, and since 2001, the World Health Organi-
zation has recommended artemisinin-based combination therapies
(ACTs) as the ﬁrst-line treatment for uncomplicated P. falciparum
malaria. Consequently, the demand for artemisinin derivatives
for use in ACTs currently overwhelms their supply. Many valuable
contributions to the total synthesis of artemisinin have been re-
ported [2–4], but the industrialization of total chemical synthesishas not yet been achieved due to the high cost of the multistep
synthesis process. The increasing demand for ACTs, along with lim-
ited supplies of plant-derived artemisinin, has led scientists to
study its biosynthesis in A. annua.
In the artemisinin pathway, the ﬁrst committed step is
mediated by amorpha-4,11-diene synthase (ADS), which converts
the common sesquiterpene precursor farnesyl diphosphate into
amorpha-4,11-diene [5,6]. Subsequently, a cytochrome P450
monooxygenase (CYP71AV1) oxidizes amorpha-4,11-diene at the
C12 position to artemisinic acid in three successive steps [7,8]. In
an earlier study, artemisinic acid was proposed as a precursor of
artemisinin [9]. However, recent data suggest that the primary
route is through the artemisinic aldehyde intermediate resulting
from the second oxidation step of CYP71AV1 [10,11]. Subse-
quently, artemisinic aldehyde is converted into artemisinin by sev-
eral other enzymatic and non-enzymatic reactions (Supplementary
Fig. 1) [12].
In addition to A. annua, the extracts of several other species,
including Artemisia afra and Artemisia absinthium in the same genus,
have been reported to show antiplasmodial activity [13–15]. How-
ever, our extensive chemical analysis failed to detect any traces of
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artemsinic acid) from these species (Suzuki et al., unpublished
data). Hence, we investigated whether these Artemisia species ex-
press genes potentially encoding the artemisinin biosynthetic
enzyme.
As a result, we isolated putative CYP71AV1 orthologs, which en-
coded proteins with an identity of more than 94% amino acid with
A. annua CYP71AV1 from both A. afra and A. absinthium. Moreover,
a comparative structural and functional analysis of CYP71AV1 and
putative orthologous proteins, combined with homology modeling
and subsequent mutational analysis, successfully identiﬁed an
amino acid residue (Ser479) that was important for the multiple
oxidations of amorpha-4,11-diene, which are catalyzed by
CYP71AV1.2. Materials and methods
2.1. Plant materials and chemical standards
A. annua was obtained from the Research Center for Medicinal
Plant Resources. A. afra was obtained from University of Pretoria.
A. absinthium was purchased at a specialty herb store (e-tisanes)
in Shizuoka, Japan.
Artemisinic acid was isolated from A. annua [16]. Artemisinic
acid was esteriﬁed with CH2N2 and then reduced to the corre-
sponding artemisinic alcohol with diisobutyl aluminum hydride.
Artemisinic alcohol was mesylated with methanesulfonyl chloride
and then reduced with lithium aluminum hydride to yield amor-
pha-4,11-diene. The product was puriﬁed using a column of silver
nitrate-coated silica gel to give amorpha-4,11-diene as a colorless
oil. Artemisinic alcohol was oxidized with MnO2 to yield the corre-
sponding artemisinic aldehyde. All compounds were identiﬁed by a
comparison of proton nuclear magnetic resonance spectroscopy
(1H NMR), carbon nuclear magnetic resonance spectroscopy (13C
NMR), and gas chromatography–mass spectrometry (GC–MS) with
reference data [11,17,18].
2.2. RT-PCR and isolation of cDNAs
Total RNA was extracted from the leaves of A. annua, A. afra, and
A. absinthium using RNAwiz (Ambion, Carlsbad, CA, USA) and trea-
ted with RNase-free DNase (Takara Bio Inc., Shiga, Japan). It was
further puriﬁed using an RNeasy Plant Mini Kit (Qiagen KK, Tokyo,
Japan) according to the manufacturer’s speciﬁcations. First-strand
cDNA synthesis was carried out using a SMART RACE cDNA Ampli-
ﬁcation Kit (Clontech/Takara Bio Inc.) with 1 lg total RNA. PCR was
performed using primers 1–2 for ADS, 3–4 for CYP71AV1, and 5–6
for ubiquitin (for primer sequences see Supplementary Table 1).
To obtain the cDNAs encoding afCYP71AV1 (GenBank ID:
AB706289) and abCYP71AV1 (GenBank ID: AB706290), RT-PCR
was conducted using KOD Plus Polymerase (Toyobo, Osaka, Japan)
with primers 3–4. The ampliﬁed fragment was cloned into pENTR/
D-TOPO (Invitrogen, Carlsbad, CA, USA) and sequenced. Three indi-
vidual clones were fully sequenced and showed no sequence
variation.
2.3. Construction of chimeric cDNAs
To generate chimeric constructs consisting of cDNA fragments
from CYP71AV1 (GenBank ID: AB706288) and abCYP71AV1, the
fragments to be fused were produced in separate PCR reactions.
Primers 3–8, 3–10, 4–7, and 4–9 were used to amplify fragments
from regions A, A–B, B–C, and C, respectively (Fig. 3A). The ob-
tained fragments were mixed at a ratio of 1:1 and subsequently
fused and ampliﬁed using primers 3–4.2.4. Site-directed mutagenesis
CYP71AV1 S307A and CYP71AV1 L369M were constructed via
two PCR steps using one forward and one reverse mutagenic pri-
mer for each site-directed mutant. The primer pairs incorporating
point mutation were primers 11–12 (CYP71AV1 S307A) and 13–14
(CYP71AV1 L369M). CYP71AV1 M483V and CYP71AV1 S479F were
constructed via one PCR with the following reverse mutagenic
primers: 15 (CYP71AV1M483V) and 16 (CYP71AV1 S479F). Coding
regions were fully sequenced to verify that no undesired mutations
had been introduced by PCR.
2.5. Yeast in vivo assays
The plasmids used in our study, pELC-GAL-P450 (galactose-
inducible expression of Lotus japonicus CPR and Artemisia species
P450, driven by the promoters GAL10 and GAL1, respectively) and
pYES3-ADH-ADS (constitutive expression of ADS driven by an
ADH1 promoter) were constructed as following sentences.
To obtain pELC-GAL-P450, the full-length cDNA was cloned via
the gateway entry vector pENTR/D-TOPO (Invitrogen) into the
Gateway-adopted version of the pELC vector [19]. The expression
of P450 and CPR was under the control of the galactose-inducible
promoters GAL1 and GAL10, respectively. pYES3-ADH-ADS was
constructed using the pYES3/CT (AUR)-Gateway-1 vector (Akashi
et al., unpublished data). The pYES3/CT (AUR)-Gateway-1 vector
was constructed by replacing PGAL1 in the CYC1TT region of
pYES3/CT (Invitrogen) with the fragment containing the ADH1 pro-
moter-terminator (PADH1-TADH1) of pAUR123 (Takara Bio Inc.),
subsequent digestion with SmaI, and ligation to the GATEWAY
conversion cassette frame B (Invitrogen).
The two vectors were introduced to Saccharomyces cerevisiae
strain INVSc1 (MATa his3D1 leu2 trp1-289 ura3-52; Invitrogen)
using Frozen-EZ Yeast Transformation II TM (Zymo Research, Ir-
vine, CA, USA). A sample harboring pYES3-ADH-ADS and pELC-
GAL-empty was used as a control. Recombinant yeast cells in syn-
thetic complete medium (10 ml) containing 2% glucose without
tryptophan and leucine (SC-W-L) were cultured at 30 C for 1 day
at 150 rpm. The cells were collected and resuspended in SC-W-L
medium (10 ml) containing 13 lg/ml hemin and 2% galactose (in-
stead of glucose) and cultured at 30 C for 1 day at 150 rpm. The
cultured samples obtained (5 ml) were disrupted by glass beads,
acid-washed (425–600 lm; Sigma–Aldrich, St. Louis, MO, USA)
and then extracted three times with ethyl acetate (5 ml). The ex-
tract was ﬁltered through a sodium sulfate column and then con-
centrated by evaporation under a stream of nitrogen gas to
minimum volume. The residue was dissolved with ethyl acetate
(500 ll) to prepare the sample for gas chromatography–mass spec-
trometry (GC–MS) analysis.
2.6. In vitro enzyme assays
Recombinant yeast harboring pELC-GAL-P450 alone was used to
obtain microsomal fractions. Yeast microsomal fractions were pre-
pared according to a previously described technique [20] except for
conditioning of the buffer. Brieﬂy, cells were washed with buffer A
(80 mM Hepes-NaOH (pH 7.2), 5 mM EGTA, 5 mM EDTA, 10 mM
KCl, and 320 mM sucrose) [21] and resuspended and incubated
in buffer B (buffer A supplemented with 10 mM b-Me). Cells were
broken using glass beads in buffer C (buffer A supplemented with
2 mM b-Me and 1 mM PMSF). Microsomal fractions were prepared
by centrifugation at 1500g for 10 min at 4 C to remove cellular
debris followed by centrifugation at 100,000g for 60 min at
4 C. The ﬁnal microsomal pellets were resuspended in a storage
buffer (50 mM potassium phosphate buffer (pH 7.4), 100 mM NaCl,
1 mM EDTA, 1.5 mM b-Me, and 20% glycerol).
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concentration of 20 lM to 2 ml McIlvaine buffer (pH 6) containing
2 mM dithiothreitol, 5 lM FAD, 5 lM FMN, 1 mM ascorbic acid,
5 mM NADPH, and 60–80 lg microsomal pellets. The reaction mix-
tures were incubated overnight and extracted with ethyl acetate
(1 ml  1, 500 ll  2) and concentrated by evaporation under a
stream of nitrogen gas to minimum volume. The residue was dis-
solved with ethyl acetate (400 ll) to prepare the sample for GC–
MS analysis. GC–MS samples for artemisinic acid analysis were
esteriﬁed with an excess of diazomethane. The conversion efﬁ-
ciency of a substrate to reaction products was calculated from
the peak area of the total ion chromatogram as follows. Diene, alco-
hol, aldehyde and acid indicates amorpha-4,11-diene, artemisinic
alcohol, artemisinic aldehyde and artemisinic acid, respectively.
diene to alcohol ¼ alcoholþ aldehydeþ acid
dieneþ alcoholþ aldehydeþ acid
 100 ð%Þalcohol to aldehyde ¼ aldehydeþ acid
alcoholþ aldehydeþ acid 100 ð%Þ2.7. Homology modeling
A BLAST [22] search was used to ﬁnd a suitable template for
modeling CYP71AV1. On the basis of the highest identity (27%),
human microsomal P450, CYP1A2 (PDB ID: 2HI4) [23] was se-
lected. Homology modeling was performed with T-coffee [24]
and Modeler [25] by threading the CYP71AV1 onto the structural
coordinates for CYP1A2. Docking calculations were conducted with
the PatchDock web server [26,27].Fig. 1. Isolated putative CYP71AV1 orthologs from A. afra and A. absinthium. (A) RT-PCR a
Ubiquitin (UBQ) was included as an internal control. (B) Alignment of deduced amino ac
GENETYX Corp., Tokyo, Japan). Identical residues are indicated by dark shading. The larg
stars denote the conserved regions in afCYP71AV1 and abCYP71AV1 that differ in CYP72.8. GC–MS analysis
GC–MS data for sesquiterpenoid analysis were corrected with
a JMS-AM SUN200 quadrupole mass spectrometer (JEOL, Tokyo,
Japan) interfaced to a model 6890 gas chromatograph (Agilent,
Santa Clara, CA, USA) operated in the electron impact mode
(70 eV). A capillary column was used under the following
conditions: HP-5MS (30 m, 0.25 mm i.d., 0.25 lm ﬁlm thickness,
J&W; Agilent) with fused silica capillary tube (1 m, 0.25 mm i.d;
GL Sciences, Tokyo, Japan); injection port temperature, 250 C;
interface temperature, 280 C; ion source temperature,
250 C; oven temperature program: 60 C rising at 3 C/min to
280 C, held for 6 min, 40 s; split ratio, 1:10; carrier gas, helium;
ﬂow rate, 0.7 ml/min. The scanning speed of the mass spectrom-
eter was 2 scans/sec from m/z 40 to m/z 350. The peaks were
identiﬁed by a comparison of GC retention time and mass spec-
tra to those of authentic compounds. Limit of detection was
2 ng/ml culture and reaction mixtures. Relative ion intensity is
shown as a percentage relative to the most intense ion (100%
intensity).3. Results
3.1. Isolation of putative CYP71AV1 orthologs
To investigate whether the Artemisia species that were reported
to have antimalarial activity expressed genes for artemisinin bio-
synthesis, RT-PCR was performed using RNA isolated from leaves
of A. afra and A. absinthium with primers designed for both start
and stop codons of ADS and CYP71AV1.nalysis of amorpha-4,11-diene synthase (ADS) and CYP71AV1 mRNA levels in leaves.
id sequences of CYP71AV1 and putative CYP71AV1 orthologs (GENETYX Version 8;
e double arrows indicate the three regions of chimeric proteins. Circled marks and
1AV1. Stars show the positions of site-directed mutations.
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artemisinin-speciﬁc pathway, were not detectable in these
Artemisia species (Fig. 1A). The same results were obtained when
RT-PCR was performed with the other 14 different primer sets.
The absence of the ADS transcript relates to the fact that no arte-
misinin and its speciﬁc intermediates were detected from these
Artemisia species.
PCR products were detected in both A. afra and A. absinthium
with the primer set for CYP71AV1. The putative full length cDNAs
encoded a polypeptide of 495 residues, which had a 94% identity
to CYP71AV1. According to the deduced amino acid sequences
from these putative CYP71AV1 orthologous cDNAs, the P450
nomenclature committee (c/o Dr. D.R. Nelson, University of Ten-
nessee, Memphis, TN) named them CYP71AV1. In this study, A. afra
CYP71AV1 and A. absinthium CYP71AV1 were named afCYP71AV1
and abCYP71AV1, respectively. These putative CYP71AV1 orthologs
share a high amino acid identity (98%) and have 23 common amino
acid residues that are different from CYP71AV1 (Fig. 1B, circled
marks and stars).Fig. 2. Armoprha-4,11-diene oxidizing activity of putative CYP71AV1 orthologs. (A) GC p
and abCYP71AV1. These P450s were co-expressed with ADS and cytochrome P450 reduct
m/z 218, and m/z 234. The detected product name is shown above the boxes. The mass sp
not detectable. (B) Deduced reactions catalyzed by afCYP71AV1 and abCYP71AV1. B
afCYP71AV1 and abCYP71AV1 catalytic pathways.3.2. Amorpha-4,11-diene oxidizing activity of putative CYP71AV1
orthologs
The potential amorpha-4,11-diene oxidizing activity of the CY-
P71AV1 orthologs was examined in an engineered yeast strain that
produces amorpha-4,11-diene endogenously. For this purpose ADS
from A. annua was expressed in yeast cells, and subsequently, each
of afCYP71AV1 or abCYP71AV1 was co-expressed with CPR (cyto-
chrome P450 reductase, a redox partner of CYP) in the ADS-
transformed yeast. Following the culture, ethyl acetate extracts
were analyzed by GC–MS.
In the ethyl acetate extract of the ADS/CPR/CYP71AV1-expressing
yeast culture, artemisinic acid was detected as the sole reaction
product of the enzymatic oxidation (Fig. 2A), indicating that CY-
P71AV1 is capable of catalyzing the three-step oxidation of amor-
pha-4,11-diene to generate artemisinic acid, as reported previously
[7,8]. Although both afCYP71AV1 and abCYP71AV1 catalyzed the
initial oxidation step at the C12 position of amoprha-4,11-diene
into artemisinic alcohol, the oxidation reaction of artemisinicroﬁles of ethyl acetate extracts from yeast strains expressing CYP71AV1, afCYP71AV1,
ase (CPR). Each box indicates the extracted ion chromatograms at m/z 204, m/z 202,
ectra for these products match the authentic standard (Supplementary Fig. 2). N.D.,
lue arrows indicate the CYP71AV1 catalytic pathway. Green arrows denote the
Fig. 3. Amorpha-4,11-diene oxidizing activity of CYP71AV1/abCYP71AV1 chimeric
proteins. (A) Chimeric cDNAs are represented by combinations of dark and light-
gray boxes representing CYP71AV1 (dark) and abCYP71AV1 (light) coding
sequences. The protein regions are indicated by letters. (B) GC proﬁles of ethyl
acetate extracts from yeast strains expressing ADS, CPR, and each chimeric gene.
Each box indicates the extracted ion chromatograms at m/z 202 (left and middle)
and m/z 234 (right). The detected product names are shown above the boxes. The
mass spectra for these products match the authentic standard (Supplementary
Fig. 2). N.D., not detectable.
Fig. 4. Effects of site-directed mutation on the successive oxidizing activity of
CYP71AV1. (A) Prediction of the 3D model of CYP71AV1 generated using the human
microsomal P450 1A2 protein (PDB ID: 2HI4). The heme is shown in magenta.
Ile290, Ser307, Lys321, Met353, Leu369, Ala409, Val468, Ser479, and Met483 are
shown in red. (B) GC proﬁles of ethyl acetate extracts from yeast strains expressing
ADS, CPR, and CYP71AV1 site-directed mutants. Each box indicates the extracted ion
chromatograms at m/z 202 (left) and m/z 234 (right). The detected product names
are shown above the boxes. The mass spectra for these products match the
authentic standard (Supplementary Fig. 2). N.D., not detectable.
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weakly (Fig. 2A). Additionally, putative reaction products of both
afCYP71AV1 and abCYP71AV1 accumulated at levels comparable
to the artemisinic alcohol detected (Fig. 2A). The putative reaction
product was not detected from the yeast without expressing ADS.
Mass spectra of the reaction product revealed a molecular ion of
M+ at m/z 220, desorption of M+–H2O at m/z 202, and a-cleavage
of M+–CH2OH at m/z 189 (Supplementary Fig. 3). Therefore, we
presumed that the reaction product was an artemisinic alcohol
isomer.
From these results, we suggest that both the oxidation activity
and the regioselectivity of CYP71AV1 orthologs are lower than
those of CYP71AV1 when comparing product accumulation pat-
terns. This difference in activity could be attributable to the 23 dif-
ferent amino acid residues in CYP71AV1 orthologs.
3.3. Amorpha-4,11-diene oxidizing activity of chimera proteins
To deﬁne the residues that deﬁne the speciﬁcity of the amor-
pha-4,11-diene oxidizing activity, chimeric cDNAs (within domainA, B, and C, 10, 4, and 9 of amino acid residues, respectively) were
constructed by fusing cDNA fragments of the CYP71AV1 and
abCYP71AV1, and were expressed in the ADS-expressing yeast
(Fig. 3A). In the ethyl acetate extracts of the chimera1 and
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nic alcohol isomer were detected, which was a similar product pat-
tern to the abCYP71AV1-expressing yeast (Fig. 3B). However, in
chimera3-expressing yeast, only artemisinic acid was detected,
which was similar to that of CYP71AV1-expressing yeast (Fig. 3B).
Both chimera1 and chimera2 contained the C region from abCY-
P71AV1, and chimera3 contained the C region from CYP71AV1,
suggesting that C regions contain the residues that determine the
oxidation activity and the regioselectivity difference between CY-
P71AV1 and putative CYP71AV1 orthologs.
3.4. Artemisinic alcohol oxidizing activity of CYP71AV1 S479F
The C region of CYP71AV1 contains nine residues of the 23 dif-
ferent amino acid residues. A homology model of CYP71AV1 based
on human microsomal P450 (CYP1A2) was constructed for the
selection of candidate residues involving the functional activity
from the nine different residues (Fig. 4A). The resultant model sug-
gested that four of the nine residues (Ser307, Leu369, Ser479, and
Met483) are located in the heme catalytic site (Fig. 4A), indicating
that these four residues are most likely the candidate residues forFig. 5. Artemisinic alcohol oxidizing activity of CYP71AV1 S479F. (A) GC proﬁles of
the extracts from in vitro assays containing amorpha-4,11-diene or artemisinic
alcohol as substrate and microsomal fractions isolated from CYP71AV1/CPR or
CYP71AV1 S479F/CPR co-expressed yeast. The boxes on the left indicatem/z 204,m/z
202, m/z 218, and m/z 248. The detected product name is shown above the boxes.
The mass spectra for these products match the authentic standard (Supplementary
Fig. 2). N.D., not detectable. (B) Docking of artemisinic alcohol (orange) into a
homology model of CYP71AV1. The C-terminal loop containing Ser479 (orange) and
Met483 (cyan) is shown in cyan.determining the regioselectivity and successive oxidation activity
of CYP71AV1.
To further investigate the role of these residues, we performed
site-directed mutagenesis experiments. CYP71AV1 was mutated to
substitute the four residues for those of abCYP71AV1 and express
them in the recombinant yeast. Artemisinic alcohol isomer was
not detected in either single point-mutant, indicating that the
difference in regioselectivity between CYP71AV1 and putative CY-
P71AV1 orthologs was probably determined by two or more resi-
dues. In CYP71AV1 S479F-expressing yeast, an accumulation of
artemisinic alcohol and negligible levels of artemisinic acid were
observed (Fig. 4B). However, the other three mutants showed no
accumulation of artemisinic alcohol (Fig. 4B).
To verify the results of CYP71AV1 S479F-expressing yeast, we
undertook an in vitro assay using yeast microsomal fractions. In
the CYP71AV1 S479F-expressing yeast microsomal fractions as-
sayed with amorpha-4,11-diene as a substrate, artemisinic alcohol
was detected as a unique product (Fig. 5A). Subsequently, we used
artemisinic alcohol as a substrate and calculated the conversion
efﬁciency into artemisinic aldehyde. The microsomal fractions that
expressed CYP71AV1 S479F exhibited a 2.9% conversion efﬁciency,
whereas CYP71AV exhibited a 57.8% conversion efﬁciency (Supple-
mentary Table 2). Therefore, we concluded that Ser479 is impor-
tant for the second oxidation reaction of CYP71AV1.4. Discussion
In this study, we isolated putative CYP71AV1 orthologous genes
from A. afra and A. absinthium. Comparative functional analysis of
CYP71AV1 and its putative orthologs, and homology modeling re-
vealed that Ser479 is important for the successive oxidation reac-
tions of CYP71AV1.
In artemisinin biosynthesis, dihydroartemisinic acid formed
from dihydroartemisinic aldhyde is thought to be a late precursor.
Therefore, the regulation of CYP71AV1 successive oxidation is
interesting because the pathway branches at the formation of
artemisinic aldehyde to give dihydroartemisinic aldehyde by the
action of artemisinic aldehyde D11(13) reductase (Dbr2) or artem-
isinic acid, which appears to be a dead end product, by the action of
CYP71AV1 and/or aldehyde dehydrogenase (Aldh1) (Supplemen-
tary Fig. 1) [12].
Six putative substrate-recognition sites (SRSs 1-6) for P450s
have been proposed in the regions of primary sequences based
on the alignment of the CYP2 family with P450cam [28]. Several
key amino acid residues that affect the reactivity have been re-
ported within the SRSs. Mutagenesis of residues within SRS6 of
multifunctional P450s, 5-epiaristolochene-1,3-dihydroxylase, and
ﬂavonoid 30,50-hydroxylase was shown to affect the oxidation reac-
tion [29,30]. In CYP71AV1, position 479 corresponds to a region
designated SRS6 (Supplementary Fig. 4). The docking of artemisinic
alcohol into the CYP71AV1model demonstrated that a loop located
in the C-terminal (C-terminal loop) covering the C12 position of
the alcohol. Ser479 is located in the loop and toward the A-helix
(Fig. 5B). Conversion of Ser into the large amino acid Phe might re-
sult in a conformational change of the C-terminal loop and subse-
quently affect the substrate binding pocket. These conformational
changes may allow the ﬁrst oxidation reaction but inhibit the sec-
ond oxidation reaction of CYP71AV1. On the other hand, no clear
effect was observed in the replacement of Met by Ver at position
483 in the loop. The similar physical properties of these residue
side chains might explain this ﬁnding.
The results here show that when Ser479 in CYP71AV1 was
substituted to a Phe, a conserved residue in both afCYP71AV1
and abCYP71AV1, the artemisinic alcohol accumulation pattern is
altered to a pattern that closely resembles that observed with
284 A. Komori et al. / FEBS Letters 587 (2013) 278–284afCYP71AV1 or abCYP71AV1. In CYP71AV3-7 of other Asteraceae
plants, which show a 80–87% identity to CYP71AV1 and germac-
rene A oxidation activity [31], the residue corresponding to
Ser479 is a Phe resembling afCYP71AV1 and abCYP71AV1 (Supple-
mentary Fig. 4). Nguyen et al. reported that germacrene A oxidase
may have subsequently evolved to accommodate amorpha-4,11-
diene for the biosynthesis of artemisinic acid [31]. Therefore, the
substitution of Phe to Ser may have been a key event in the evolu-
tion of ancestral P450s toward CYP71AV1.
A transcript of ADS was not detected in afCYP71AV1- or abCY-
P71AV1-expressing leaves (Fig. 1A). Additionally, GC–MS analysis
could not detect artemisinin and its intermediates in these samples
(Suzuki et al., unpublished data). Therefore, the natural substrate
of afCYP71AV1 and abCYP71AV1, in planta might be a sesquiter-
pene other than amorpha-4,11-diene. The fact that CYP71AV3-8
isolated from plants that do not produce artemisinin can oxidize
amorpha-4,11-diene and other sesquiterpenoids (germacrene A
and/or valencene) [31,32] also supports this hypothesis.
Here, we demonstrated that putative CYP71AV1 orthologs can
be used for investigating the structure–function relationships of
CYP71AV1. We also determined that eight species of Artemisia have
putative CYP71AV1 orthologous genes, which were shown to have
different residues from CYP71AV1, afCYP71AV1, abCYP71AV1, and
CYP71AV3-8 (Supplementary Fig. 4). Therefore, isolation and func-
tional analysis of the variety of putative CYP71AV1 orthologs dis-
tributed in the genus Artemisia might enable a more detailed
investigation of structure–function relationships and allow the cre-
ation of more efﬁcient enzymes that could be useful for the bio-
synthesis of artemisinin.
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